What postoperative surveillance and need for additional surgery or adjuvant therapy are recommended for a patient with a 1.1 cm, grade 1 goblet‑cell adenocarcinoma of the appendix that was completely resected by appendectomy?

Management of 1.1 cm Grade 1 Goblet Cell Adenocarcinoma After Appendectomy

For a completely resected 1.1 cm grade 1 goblet cell adenocarcinoma of the appendix, right hemicolectomy is required for definitive oncologic management, followed by 10-year surveillance without adjuvant chemotherapy.

Additional Surgery Required

Right hemicolectomy is mandatory for this tumor 1. Goblet cell adenocarcinomas behave more aggressively than typical appendiceal neuroendocrine tumors and require oncologic resection regardless of size 1, 2. The 2012 Gut guidelines explicitly state: "Goblet cell appendix tumours always require right hemicolectomy because they behave in a much more aggressive way" 1.

Key Surgical Considerations:

• Right hemicolectomy with lymphadenectomy provides proper staging and removes regional lymph nodes at risk for metastasis 1
• At least 12 lymph nodes should be examined for adequate staging 3
• In female patients, bilateral salpingo-oophorectomy should be strongly considered due to the 50% risk of ovarian metastases in women with goblet cell adenocarcinoma 4, 5. The guideline development group specifically notes increased risk of bilateral ovarian metastases with goblet cell tumors 1

Why Simple Appendectomy is Insufficient:

The evidence consistently demonstrates that goblet cell adenocarcinomas have unpredictable biological behavior with:

• Higher malignant potential than conventional carcinoids 2, 6, 5
• Risk of local recurrence and delayed metastases even in early stages 2
• Lymph node involvement in approximately 9% of cases at diagnosis 5
• 20% risk of metastatic behavior 5

Adjuvant Chemotherapy

Adjuvant chemotherapy is NOT recommended for completely resected, node-negative goblet cell adenocarcinoma. The evidence shows minimal effectiveness:

• 5-fluorouracil and leucovorin regimens are "minimally effective" against goblet cell carcinoma 4
• In a Mayo Clinic series, adjuvant chemotherapy showed no survival benefit (32% vs 27% 5-year survival, p=0.151) 4
• Chemotherapy is reserved for cases with obvious metastatic spread 5

Surveillance Protocol

10-year surveillance is required for goblet cell adenocarcinoma due to risk of late recurrence 1, 2, 5:

Surveillance Schedule:

Years 1-3:

• Every 3 months: Physical examination, CEA testing, CT chest/abdomen/pelvis
• Colonoscopy at 1 year post-surgery 7

Years 4-5:

• Every 6 months: Physical examination, CEA testing, CT imaging

Years 6-10:

• Annually: Physical examination, CEA testing, CT imaging
• Colonoscopy every 3-5 years based on findings 7

Rationale for Extended Surveillance:

• Goblet cell adenocarcinomas have "unpredictable biological behavior even in early stages" 2
• Local recurrence and delayed metastases may occur years after initial treatment 2, 5
• "Lifelong surveillance is warranted" according to multiple sources 2, 5
• The 10-year surveillance period is specifically recommended in guidelines 1

Important Surveillance Considerations:

• Colonoscopy surveillance is critical: There is a 43% risk of synchronous or metachronous colorectal adenocarcinoma in patients with goblet cell adenocarcinoma 6
• First colonoscopy should occur 1 year after surgery, then every 3 years if normal 7
• In women, pelvic imaging should specifically evaluate for ovarian metastases given the high propensity for ovarian involvement 1, 4

Common Pitfalls to Avoid

1. Do not treat this as a typical appendiceal neuroendocrine tumor - goblet cell adenocarcinomas require more aggressive management 1
2. Do not skip right hemicolectomy - even with complete appendectomy margins, completion colectomy is necessary for proper staging and regional lymph node assessment 1
3. Do not use standard 5-year cancer surveillance - these tumors require 10-year follow-up due to late recurrence patterns 1, 2
4. In female patients, do not overlook ovarian surveillance or prophylactic oophorectomy discussion - 50% develop ovarian metastases 4